Shinpoong Phar (019170)

Seoul
75,100.00
+10,800.00(+16.80%)
  • Volume:
    8,221,040
  • Bid/Ask:
    75,100.00/75,200.00
  • Day's Range:
    65,100.00 - 78,600.00

019170 Overview

Prev. Close
64,300
Day's Range
65,100 - 78,600
Revenue
197.56B
Open
65,100
52 wk Range
18,750 - 214,000
EPS
39.33
Volume
8,221,040
Market Cap
3.57T
Dividend (Yield)
100.00 (0.16%)
Average Vol. (3m)
693,957
P/E Ratio
1,634.72
Beta
0.8
1-Year Change
255.91%
Shares Outstanding
49,271,029
Next Earnings Date
Jun 02, 2021
What is your sentiment on Shinpoong Phar?
or
Market is currently closed. Voting is open during market hours.

Shinpoong Phar News

  • Markets in Q3: The charge before the storm
    • ByReuters-
    • 2

    By Marc Jones LONDON (Reuters) - Financial markets roared into the second half of the year in full-throttle comeback mode. The only problem was that the coronavirus came back too....

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellBuy
Technical IndicatorsBuyBuyStrong BuyBuyBuy
SummaryBuyBuyStrong BuyNeutralBuy

Shinpoong Phar Company Profile

Shinpoong Phar Company Profile

Employees
840

Shin Pooong Pharm., Co. Ltd is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. The Company's product portfolio consists of antibiotics, cardiovascular drugs, anti-cancer drugs, psychoneurotic drugs, antirheumatic drugs, antidiabetics, antifungal agents, antihistamines, antiviral agents, benign prostatic hyperplasia (BPH) drugs and trichogens. The Company also provides active pharmaceutical ingredients (APIs) synthesized by the Company, including non-steroidal anti-inflammatory drugs (NSAIDs), cardiovascular drugs, anti-ulcer drugs, respiratory drugs, antispasmodics drugs and others. The Company distributes its products within domestic market and to overseas markets.

Read More
  • high quality
    0
    • LINE ID zhengqiang99
      0
      • 。。。
        0
        • Scientists suggest that anti-malarial drug, PYAMAX could be repurposed to treat COVID-19 https://www.news-medical.net/news/20201020/Scientists-suggest-that-anti-malarial-drugs-could-be-repurposed-to-treat-COVID-19.aspx
          0
          • https://www.dfnetresearch.com/covid-19-treatment/MMV & Shin Poong Pharm
            0
            • Pyramax (Artesunate+pyronaridine) will be the COVID-19 pandemic closure.
              0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.